Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...